Nice to see some conservative assumptions in there.Funny how...

Nice to see some conservative assumptions in there.

Funny how they increased there valuations of HRV and LANI after the site visit... I wonder what was said, or what hints given. It's quite a dramatic shift in valuation simply because of a site visit...

Also interesting to see the LANI market share assumption is only at 10%. After licensing I'm sure the pharma partner could do better given the many advantages of LANI... but let's wait and see.

HRV assumes 25% chance of success, that must be commercial success rather than probability of getting FDA approved which could be around 60-70% now it's passed a phase II trial. Anyhow good to see such conservative assumptions still getting a valuation over $3.